Atara Biotherapeutics (NASDAQ:ATRA) Upgraded by StockNews.com to Hold
StockNews.com upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA – Free Report) from a sell rating to a hold rating in a report published on Thursday. Separately, HC Wainwright reaffirmed a buy rating and issued a $28.00 price target on shares of Atara Biotherapeutics in a research note on Tuesday, September 26th. Check Out Our Latest Report […]
More Stories
Hochschild Mining (LON:HOC) Stock Price Crosses Above 200 Day Moving Average – Time to Sell?
Hochschild Mining plc (LON:HOC – Get Free Report)’s share price passed above its two hundred day moving average during trading...
Tortoise Pipeline & Energy Fund (NYSE:TTP) Shares Pass Above 200 Day Moving Average – Time to Sell?
Tortoise Pipeline & Energy Fund, Inc. (NYSE:TTP – Get Free Report) shares crossed above its 200-day moving average during trading...
K-Bro Linen (TSE:KBL) Stock Price Passes Above 200-Day Moving Average – Should You Sell?
K-Bro Linen Inc. (TSE:KBL – Get Free Report)’s stock price passed above its 200-day moving average during trading on Thursday...
Rep. Lloyd Doggett Purchases Shares of The Coca-Cola Company (NYSE:KO)
Representative Lloyd Doggett (D-Texas) recently bought shares of The Coca-Cola Company (NYSE:KO). In a filing disclosed on January 08th, the...
Seres Therapeutics Provides Corporate Updates and Financial Results
On January 9, 2025, Seres Therapeutics, Inc. (NASDAQ: MCRB) released significant updates regarding its recent achievements and financial standing. The...
Cohort (LON:CHRT) Stock Price Crosses Above 200-Day Moving Average – Here’s Why
Shares of Cohort plc (LON:CHRT – Get Free Report) crossed above its 200-day moving average during trading on Thursday ....